BioVie Inc - Class A
Research BioVie Inc - Class A (BIVI) on Bullrun: market cap USD 10.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIVI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.48M
- Financial periodFY2026
- RevenueUSD 0
- Net income-USD 22.07M
- Free cash flow-USD 19.02M
Valuation Snapshot
latest market cap is USD 10.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 0 | -USD 22.07M | -USD 19.02M | n/a | n/a | USD 8.98M | USD 275.43K | USD 10.27M |
| FY2025 | USD 0 | -USD 17.54M | -USD 19.03M | n/a | -12.12 | USD 17.54M | USD 349.89K | USD 19.01M |
| FY2024 | USD 0 | -USD 32.12M | -USD 27.95M | n/a | -73.05 | USD 23.84M | USD 6.11M | USD 15.51M |
| FY2023 | USD 0 | -USD 50.26M | -USD 40.25M | n/a | -15.47 | USD 19.46M | USD 14.42M | USD 15.34M |
| FY2022 | USD 0 | -USD 26.08M | -USD 18.99M | n/a | -1.06 | USD 18.64M | USD 12.26M | USD 3.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.48M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.75M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 36.90M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 47.55M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 252.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 112.41M | n/a | n/a | n/a |
About BioVie Inc - Class A
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioVie Inc - Class A's market cap?
BioVie Inc - Class A's market capitalization is USD 10.48M.
What does BioVie Inc - Class A do?
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.